Table 2 Representative clinical trials treating diseases from a redox perspective
From: Redox regulation: mechanisms, biology and therapeutic targets in diseases
Drug | Indication | Targeted mechanism | Official title | Phase | NCT number |
|---|---|---|---|---|---|
Curcumin and Ginkgo extract | Alzheimer’s Disease | NRF2 activator | A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer’s Disease | Phase II | NCT00164749 |
Glutathione | Alzheimer’s Disease | Buffering ROS | Glutathione, Brain Metabolism and Inflammation in Alzheimer’s Disease | Early Phase I | NCT04740580 |
Edaravone | Alzheimer’s Disease | NRF2 activator | Alzheimer Study Using oRal Edaravone | Phase II | NCT05323812 |
Flos Gossypii Flavonoids | Alzheimer’s Disease | NRF2 activator | Efficacy and Safety of Flos Gossypii Flavonoids Tablet in the Treatment of Alzheimer’s Disease | Phase II | NCT05269173 |
Lipoic acid and fish oil | Alzheimer’s Disease | NRF2 activator | Fish Oil and Alpha Lipoic Acid in Treating Alzheimer’s Disease | Phase II | NCT00090402 |
Lipoic Acid and Omega-3 Fatty Acids | Alzheimer’s Disease | NRF2 activator | Lipoic Acid and Omega-3 Fatty Acids in Alzheimer’s Disease | Phase II | NCT01058941 |
N-acetylcysteine | Parkinson’s Disease | Buffering ROS | Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson’s Disease | Phase II | NCT02212678 |
N-acetylcysteine | Gaucher’s Disease and Parkinson’s Disease | Buffering ROS | Intravenous N-acetylcysteine for the Treatment of Gaucher’s Disease and Parkinson’s Disease | Phase I | NCT01427517 |
Green Tea Polyphenol | Parkinson’s Disease | NRF2 activator | Efficacy and Safety of Green Tea Polyphenol in De Novo Parkinson’s Disease Patients | Phase II | NCT00461942 |
Glutathione | Parkinson’s Disease | Buffering ROS | Glutathione in the Treatment of Parkinson’s Disease | Phase II | NCT01177319 |
Coenzyme Q10 | Parkinson’s Disease | NRF2 activator | Parkinson’s Disease Treatment with Coenzyme Q10 | Phase II | NCT00004731 |
N-acetylcysteine | Head and Neck Neoplasms | Buffering ROS | Evaluation Of the Use Of N-Acetylcysteine Attenuating Cisplatin-Induced Toxicities By Oxidative Stress In Head And Neck Cancer Patients | Phase IV | NCT02241876 |
Flavonoids | Colorectal Cancer | NRF2 activator | Dietary Bioflavonoid Supplementation for the Prevention of Neoplasia Recurrence | Phase II | NCT00609310 |
Sulforaphane | Bladder cancer | NRF2 activator | Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention | Phase II | NCT03517995 |
Curcumin | Prostate Cancer | NRF2 activator | Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance | Phase III | NCT03769766 |
GC4419 | Radiation-Induced Oral Mucositis | SOD mimic | A Study of the Effects of GC4419 on Radiation-Induced Oral Mucositis in Patients with Head/Neck Cancer | Phase II | NCT02508389 |
Ebselen | Meniere’s Disease | GPx mimic | SPI-1005 for the Treatment of Meniere’s Disease (STOPMD-3) | Phase III | NCT04677972 |
ALT-2074 | Coronary Artery Disease | GPx mimic | Evaluation of ALT-2074 in Subjects with Type 2 Diabetes, Haptoglobin Type 2-2 Genotype and Coronary Artery Disease | Phase II | NCT00491543 |
Quercetin | COPD | NRF2 activator | Beneficial Effects of Quercetin in COPD | Phase II | NCT06003270 |
Erdosteine | COPD | Buffering ROS | The Efficacy and Safety of Erdosteine in COPD | Phase III | NCT01032304 |
Sulforaphane | COPD | NRF2 activator | Broccoli Sprout Extracts Trial to See if NRF2 is Enhanced by Sulforaphane Treatment in Patients with COPD (BEST) | Phase II | NCT01335971 |
Fisetin | Peripheral Arterial Disease | NRF2 activator | Fisetin to Reduce Senescence and Mobility Impairment in PAD | Phase II | NCT06399809 |
Curcumin | Type 2 Diabetes Mellitus | NRF2 activator | Curcumin for Type 2 Diabetic Patients | Phase IV | NCT01052597 |
Ginkgo Biloba Extract | Type 2 Diabetes Mellitus | NRF2 activator | Ginkgo Biloba Extract and the Insulin Resistance Syndrome | Phase II | NCT00032474 |
N-Acetylcysteine and Arginine | Type 2 Diabetes Mellitus | Buffering ROS | N-Acetylcysteine and Arginine Administration in Diabetic Patients | Phase IV | NCT00569465 |
Melatonin | Type 2 Diabetes Mellitus | NRF2 activator | Melatonin’s Effects on the Treatment of Diabetes Mellitus | Early Phase I | NCT02691897 |
Fenofibrate and Coenzyme Q10 | Type 2 Diabetes Mellitus | NRF2 activator | A Randomised, Double-Blind, Placebo-Controlled Study Assessing the Effect of Fenofibrate, Coenzyme Q10 and Their co-Administration on Ventricular Diastolic Function in Patients With Type 2 Diabetes | Phase II | NCT00703482 |
Curcumin | NAFLD | NRF2 activator | Curcumin for Pediatric Non-alcoholic Fatty Liver Disease | Phase II | NCT04109742 |
N-Acetylcysteine | NAFLD | Buffering ROS | N-acetylCysteine and Patients With Non-alcoholic Fatty Liver Disease | Phase III | NCT05589584 |
Lipoic acid | NAFLD | NRF2 activator | Effect of Alpha Lipoic Acid on Non-alcoholic Fatty Liver Diseases | Phase IV | NCT04475276 |
Coenzyme Q10 | NAFLD | NRF2 activator | The Effect of Coenzyme Q10 on Endothelial, Vascular and Myocardial Function | Phase II | NCT05941910 |
Glucocorticoid and sinomenine | Knee Osteoarthritis | NRF2 activator | Sinomenine Versus Glucocorticoid for Knee OA | Phase III | NCT05764304 |
Astaxanthin | Knee Osteoarthritis | NRF2 activator | Effect of Astaxanthin in Moderate to Severe Knee Osteoarthritis | Phase II | NCT05437601 |
Grape Seed Extract | Heart Failure | NRF2 activator | Physiological Effects of Grape Seed Extract in Diastolic Heart Failure | Phase I | NCT01185067 |
Lipoic Acid | Heart Failure | NRF2 activator | Clinical Study of Lipoic Acid on Ischemic Heart Failure | Phase IV | NCT03491969 |
N-Acetylcysteine | Heart Failure with Chronic Renal Failure | Buffering ROS | N-Acetylcysteine in Heart Failure with Coexistent Chronic Renal Failure | Phase III | NCT00532688 |
